Latest Education News

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

Arena REIT reported a robust half-year performance for HY2026, with net profit rising to $110 million and earnings per security up 5.4%. The company reaffirmed its FY2026 distribution guidance, underpinned by strong rental growth and disciplined capital management.

ASB’s half-year results show a modest 1% rise in cash net profit, driven by growth in home, business, and rural lending alongside a 5% increase in customer deposits. The bank is investing heavily in technology, customer experience, and social housing initiatives to support New Zealand’s long-term prosperity.

NexGen Energy is advancing through the final Canadian Nuclear Safety Commission hearing for its Rook I uranium project, buoyed by strong Indigenous community support and over a decade of environmental and social groundwork.

G8 Education has announced a significant $350 million goodwill impairment for FY25, reflecting ongoing sector pressures. Despite this, the company maintains its EBIT guidance but suspends dividends and pauses its share buyback program.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Embark Early Education has removed major hurdles from its off-market takeover bid for Mayfield Childcare, signalling stronger momentum towards acquisition.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Charter Hall Social Infrastructure REIT (CQE) has reported robust first-half FY26 results, driven by strategic acquisitions and strong rental growth, prompting an upgrade to its full-year earnings and distribution guidance.

Charter Hall Social Infrastructure REIT (CQE) reported a robust half-year performance with a 51.6% jump in statutory profit and upgraded its FY26 distribution guidance, underpinned by strategic acquisitions and refinancing.